Breaking News: Australians with severe obesity and heart disease are about to get a much-needed boost! The government is expanding access to Wegovy, a GLP-1 medication, through the Pharmaceutical Benefits Scheme (PBS). This move promises to make this potentially life-changing treatment more accessible, but it's not without its complexities. Let's dive in.
Health Minister Mark Butler kicked off the new year with a promise: Wegovy will be subsidized for a specific group of Australians. The focus? Individuals with severe obesity (a Body Mass Index, or BMI, of 35 or higher) and established cardiovascular disease. This is a significant step, as it addresses a critical health need for those at high risk.
The Pharmaceutical Benefits Advisory Committee (PBAC), the experts behind the PBS, also recognized the potential of Wegovy for prevention. But here's where it gets controversial: They acknowledged the drug's benefits but raised concerns about affordability and potential adverse events if it were available to everyone. This highlights the delicate balance between providing access and managing healthcare costs.
Minister Butler shared the news on Channel Seven's Sunrise program, emphasizing the government's commitment to listing every recommendation from the PBAC. He also highlighted the current financial burden on Australians, with over 400,000 people currently paying out-of-pocket, sometimes up to $4,000-$5,000 annually, for these medications. This is clearly an equity issue, as access to this treatment has been limited to those who can afford it.
Currently, GLP-1 drugs are available on the PBS only for people with type 2 diabetes. This expansion marks a significant shift in how obesity is treated and managed.
In 2025, at Mr. Butler's request, the PBAC conducted a review to ensure equitable access to GLP-1 obesity treatments. They identified priority groups, including those with cardiovascular disease, Aboriginal and Torres Strait Islander patients with obesity-related health issues, and individuals with specific types of obesity. The PBAC emphasized the importance of support for diet and exercise and suggested that digital models could help provide more equitable access. However, they strongly advised against mandatory requirements for additional services, as this could create barriers to accessing the treatment.
At the same meeting, the PBAC recommended subsidizing semaglutide (the active ingredient in Wegovy) for adults with established cardiovascular disease and obesity. Patients must have experienced a cardiovascular event like a heart attack or stroke. The PBAC considered different BMI cut-offs, ultimately deciding to limit access to those with a BMI of 35 kg/m² or higher, or 32.5 kg/m² or higher for people of Asian, Aboriginal, or Torres Strait Islander descent. This is to ensure the treatment is targeted towards those most in need.
And this is the part most people miss: The PBAC wanted the manufacturer, Novo Nordisk Pharmaceuticals Pty Ltd, to lower the drug's price. They believed the company's assumptions were inaccurate and that they had overstated the benefits of semaglutide, particularly regarding how long the benefits would last after stopping treatment. The PBAC also recognized the risk of people accessing the subsidy outside the proposed criteria, so they advised a risk-sharing agreement to manage the financial implications for the government.
The PBAC also recommended a "slow and managed" rollout of the PBS access to help manage uncertainties around long-term use and outcomes.
Related developments include the RACGP's updated position on obesity prevention and management in March 2025, which recommended increased government support for clinical services and equitable access to bariatric metabolic surgery and PBS-subsidized medications. In December of the same year, the WHO issued new guidelines with conditional recommendations for using these therapies to support people living with obesity. The guidelines emphasize a comprehensive approach that includes healthy diets, physical activity, and support from health professionals.
The WHO's main recommendations include: GLP-1 therapies may be used by adults, excluding pregnant women, for long-term obesity treatment, although there are limited data on their long-term efficacy and safety. Intensive behavioral interventions, including healthy diet and physical activity, may be offered alongside GLP-1 therapies to enhance treatment outcomes.
Dietitians Australia welcomed the recommendation but warned that safeguards are needed. They emphasize the importance of appropriate nutrition support to prevent malnutrition, loss of muscle and bone mass, and disordered eating. CEO Magriet Raxworthy stated that "Lasting improvements in health are achieved through comprehensive, multidisciplinary care that includes funded access to evidence-based nutrition support before, during and after treatment."
What do you think about this new development? Do you believe the government is striking the right balance between access and cost? Share your thoughts in the comments below!**
